Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2025 08:30 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Announces Reverse Stock Split

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage...
December 11, 2024 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a...
December 02, 2024 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B’s Late-Clinical Stage Candidate to Treat Parkinson’s Disease Hepion’s Board Unanimously Recommends Shareholders Approve...
November 11, 2024 08:00 ET | Source: Hepion Pharmaceuticals, Inc.

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...